Business Description
Kezar Life Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US49372L1008
Description
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.64 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -14.4 | |||||
| 3-Year EPS without NRI Growth Rate | -11.4 | |||||
| 3-Year FCF Growth Rate | -10.9 | |||||
| 3-Year Book Growth Rate | -5.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.58 | |||||
| 9-Day RSI | 51.43 | |||||
| 14-Day RSI | 49.53 | |||||
| 6-1 Month Momentum % | 9.93 | |||||
| 12-1 Month Momentum % | -62.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.66 | |||||
| Quick Ratio | 11.66 | |||||
| Cash Ratio | 11.35 | |||||
| Days Sales Outstanding | 365 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.2 | |||||
| Shareholder Yield % | -7.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1503.39 | |||||
| Net Margin % | -1455.29 | |||||
| FCF Margin % | -1180.55 | |||||
| ROE % | -43.98 | |||||
| ROA % | -38.65 | |||||
| ROIC % | -465.72 | |||||
| ROC (Joel Greenblatt) % | -805.94 | |||||
| ROCE % | -40.29 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.38 | |||||
| PB Ratio | 0.31 | |||||
| Price-to-Tangible-Book | 0.31 | |||||
| EV-to-EBIT | 1.21 | |||||
| EV-to-EBITDA | 1.23 | |||||
| EV-to-Revenue | -17.38 | |||||
| EV-to-FCF | 1.48 | |||||
| Price-to-Net-Current-Asset-Value | 0.34 | |||||
| Price-to-Net-Cash | 0.35 | |||||
| Earnings Yield (Greenblatt) % | 82.74 | |||||
| FCF Yield % | -136.56 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kezar Life Sciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.559 | ||
| EPS (TTM) (€) | -1.307 | ||
| Beta | 0.69 | ||
| Volatility % | 71.83 | ||
| 14-Day RSI | 49.53 | ||
| 14-Day ATR (€) | 0.03102 | ||
| 20-Day SMA (€) | 0.72875 | ||
| 12-1 Month Momentum % | -62.38 | ||
| 52-Week Range (€) | 0.63 - 2.8 | ||
| Shares Outstanding (Mil) | 72.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kezar Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kezar Life Sciences Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kezar Life Sciences Inc Frequently Asked Questions
What is Kezar Life Sciences Inc(FRA:2KZ)'s stock price today?
The current price of FRA:2KZ is €0.74. The 52 week high of FRA:2KZ is €2.80 and 52 week low is €0.63.
When is next earnings date of Kezar Life Sciences Inc(FRA:2KZ)?
The next earnings date of Kezar Life Sciences Inc(FRA:2KZ) is 2024-05-10 Est..
Does Kezar Life Sciences Inc(FRA:2KZ) pay dividends? If so, how much?
Kezar Life Sciences Inc(FRA:2KZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers